D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
Stephen V. Liu,Susan Groshen,Karen Kelly,Karen L. Reckamp,Chandra P. Belani,Timothy W. Synold,Amir Goldkorn,Barbara J. Gitlitz,Barbara J. Gitlitz,Mihaela C. Cristea,I-Yeh Gong,Thomas J. Semrad,Yucheng Xu,Tong Xu,Marianna Koczywas,David R. Gandara,Edward M. Newman +16 more
TL;DR: The combination of topotecan and oral tivantinib was not tolerable in this patient population and the addition of G-CSF to attenuate neutropenia did not improve tolerability.
Journal ArticleDOI
A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).
Giorgio V. Scagliotti,Dong Wan Kim,Alice T. Shaw,Sai-Hong Ignatius Ou,Gregory J. Riely,Scott N. Gettinger,Benjamin Besse,Michael Thomas,Ravi Salgia,Keith D. Wilner,Cynthia Huang Bartlett,Anna Polli,David R. Gandara +12 more
TL;DR: This retrospectively assessed objective response rate (ORR) and time to progression (TTP) in pts who received PEM prior to CRIZ in previously treated ALK+ NSCLC and ORR with CriZ post-PEM was assessed.
Journal ArticleDOI
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.
TL;DR: The common arm methodology provides a template for identifying and interpreting patient outcome differences across populations, and is an instructive lesson in the burgeoning era of clinical trials globalization.
Journal ArticleDOI
Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer
Yun Yen,James H. Doroshow,Lucille Leong,D. Lim,Lawrence D. Wagman,Robert J. Morgan,Paul Frankel,Heinz-Josef Lenz,David R. Gandara,Stephen Shibata +9 more
TL;DR: Oxaliplatin as a single agent has demonstrated potential activity in the treatment of poor prognosis HCC; accrual to this study will continue past the interim analysis.
Journal ArticleDOI
O-192a SWOG 0023: A randomized phase III trial of cisplatin/etoposide(PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC)
Karen Kelly,Laurie E. Gaspar,K. Chanksy,Kathy S. Albain,James R. Jett,Y. Ung,John Crowley,David R. Gandara +7 more